An international research team led by the University of Michigan Life Sciences Institute is changing the understanding of the key cellular and molecular events that trigger graft-versus-host disease, an often fatal complication ...
Mar 20, 2017
0
25
Researchers at Mount Sinai Health System have discovered a way to predict whether blood cancer patients who received a bone marrow transplant will develop graft-versus-host disease, a common and often lethal complication, ...
Feb 9, 2017
0
1
Scientists in Germany have developed a new approach that may prevent leukemia and lymphoma patients from developing graft-versus-host disease (GvHD) after therapeutic bone marrow transplants. The researchers describe the ...
Aug 15, 2016
0
5
A University of Colorado Cancer Center study compared outcomes of leukemia patients receiving bone marrow transplants from 2009-2014, finding that three years post transplant, the incidence of severe chronic graft-versus-host ...
Jul 26, 2016
0
374
Scientists in Manchester, who have developed a stem cell gene therapy to reverse a fatal childhood illness, have agreed to work with a new therapeutics company to test it in a human trial.
May 11, 2016
0
14
(HealthDay)—Donor Epstein-Barr virus (EBV) serostatus influences incidence of graft-versus-host disease (GVHD) in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation (allo-HSCT), according ...
Apr 19, 2016
0
0
Bone marrow transplantation is a life-saving therapy for many patients with blood cancers like leukemias and lymphomas. Currently, the gold standard blood-generating stem cells are obtained from a donor, a sibling, with a ...
Oct 7, 2015
0
15
Targeting exhausted immune cells may change the prognosis for patients with acute myeloid leukemia (AML) relapse after a stem cell transplant, according to Penn State College of Medicine researchers.
Sep 10, 2015
0
15
For years, medicine has relied on self-reported race/ethnicity as the basis of an array of decisions, from risk for disease to matching organ donors. Now, a study led by researchers at UC San Francisco has found that when ...
Aug 24, 2015
0
35
More than 60 percent of patients with Epstein-Barr virus–associated lymphoproliferative disorder (EBV-LPD) that was not responding to standard rituximab (Rituxan) treatment responded to a new type of immunotherapy called ...
Apr 20, 2015
0
21
